

University of Dundee

Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer

Al-hattali, Samia; Vinnicombe, Sarah J.; Gowdh, Nazleen Muhammad; Evans, Andrew; Armstrong, Sharon; Adamson, Douglas

Published in:
Cancer Imaging

DOI:
[10.1186/s40644-019-0279-4](https://doi.org/10.1186/s40644-019-0279-4)

Publication date:
2019

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Al-hattali, S., Vinnicombe, S. J., Gowdh, N. M., Evans, A., Armstrong, S., Adamson, D., Purdie, C. A., & Macaskill, E. J. (2019). Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer. *Cancer Imaging*, 19(1), 1-9. [91]. <https://doi.org/10.1186/s40644-019-0279-4>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

Open Access



Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer

Samia Al-Hattali¹, Sarah J. Vinnicombe^{2,3}, Nazleen Muhammad Gowdh⁴, Andrew Evans⁴, Sharon Armstrong⁵, Douglas Adamson⁵, Colin A. Purdie⁶ and E. Jane Macaskill^{1*} 

Abstract

Background: In patients who have had axillary nodal metastasis diagnosed prior to neoadjuvant chemotherapy for breast cancer, there is little consensus on how to manage the axilla subsequently. The aim of this study was to explore whether a combination of breast magnetic resonance imaging (MRI) assessed response and primary tumour pathology factors could identify a subset of patients that might be spared axillary node clearance.

Methods: A retrospective data analysis was performed of patients with core biopsy-proven axillary nodal metastasis prior to commencement of neoadjuvant chemotherapy (NAC) who had subsequent axillary node clearance (ANC) at definitive breast surgery. Breast tumour and axillary response at MRI before, during and on completion of NAC, core biopsy tumour grade, tumour type and immunophenotype were correlated with pathological response in the breast and the number of metastatic nodes in the ANC specimens.

Results: Of 87 consecutive patients with MRI at baseline, interim and after neoadjuvant chemotherapy who underwent ANC at time of breast surgery, 33 (38%) had no residual macrometastatic axillary disease, 28 (32%) had 1–2 metastatic nodes and 26 (30%) had more than 2 metastatic nodes. Factors that predicted axillary nodal complete response were MRI complete response in the breast ($p < 0.0001$), HER2 positivity ($p = 0.02$) and non-lobular tumour type ($p = 0.015$).

Conclusion: MRI assessment of breast tumour response to NAC and core biopsy factors are predictive of response in axillary nodes, and can be used to guide decision making regarding appropriate axillary surgery.

Keywords: Neoadjuvant chemotherapy, Axilla lymph node, Breast cancer, Magnetic resonance imaging, Sentinel node biopsy

Introduction

In the past two decades, sentinel node biopsy (SNB) has become standard practice for surgically staging the axilla in patients having primary surgery for clinically node-negative breast cancers, replacing the more morbid procedure of axillary node clearance (ANC). With increasing use of neoadjuvant chemotherapy (NAC) to downsize breast tumours to achieve breast conservation, there is little consensus on how to manage the axilla,

with varying practices including SNB before or after chemotherapy and ANC [1]. In many units, ANC has remained the definitive axillary procedure after NAC if pre-treatment axillary ultrasound (AUS) and core biopsy confirmed nodal positivity. However, NAC has been demonstrated to eradicate nodal metastasis in up to 40% of patients with human epidermal growth factor receptor 2 (HER2) negative tumours, and up to 75% of HER2 positive patients treated with trastuzumab [2–5].

The feasibility and accuracy of SNB post-NAC in clinically node-negative patients has been established, with false-negative rates (FNR) of 8–11% [6–12]. A recent meta-analysis of the accuracy and reliability of sentinel

* Correspondence: ejanemacaskill@nhs.net

¹Department of Breast Surgery, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

lymph node biopsy after NAC in patients with initial biopsy-proven node-positive breast cancer demonstrated a false-negative rate with use of dual techniques of 11% compared with 19% with single mapping [13]. It also confirmed findings from previous studies showing that a higher number of nodes removed improved accuracy (FNR 20% when one node was removed, 12% with two nodes removed and 4% with removal of three or more nodes) [14–17].

It is known that the response within axillary nodal metastases correlates with that seen in the breast tumour [14, 18]. However, it would be advantageous to determine pre-operatively which patients have had a sufficiently good response to NAC in the axilla to allow potential downstaging of axillary surgery and avoidance of the morbidity of an unnecessary ANC.

The accuracy of MRI in predicting the presence of residual breast disease after NAC has been demonstrated in several studies and systematic reviews [19–21], with high negative predictive values (NPV) for pathological Complete Response (pCR), particularly in HER2 positive and triple negative disease [22]. What is not clear is the extent to which MRI reflects residual axillary nodal disease and response in the axilla in the context of neoadjuvant chemotherapy. Indeed, a systematic review of non-invasive nodal restaging in node-positive patients after NAC from 2015 found extreme heterogeneity precluding pooled analysis, and highly variable reported positive predictive values for axillary pathological complete response. It concluded that there were no accurate non-invasive restaging techniques [23]. Thus, this remains an area of unmet clinical need.

The aim of this study was to attempt to identify a subset of patients defined by MRI assessed response and primary tumour pathology factors who might be spared ANC.

Methods

This was a retrospective audit of data from a consecutive series of patients with a pathological diagnosis of breast cancer and proven nodal metastasis who received NAC within a single centre between September 2010 to June 2015. Only patients who had undergone ultrasound-guided core biopsy of ultrasonographically abnormal nodes (cortical thickness > 2.3 mm) with proven axillary node metastasis prior to starting chemotherapy were included. After completion of NAC, all patients underwent axillary node clearance (ANC) as per the standard local policy, regardless of the response. Local ethical approval was obtained for collection, analysis and presentation of data.

Patients were scheduled for breast MRI to assess the primary tumour and axilla before (pre-treatment), after 3 cycles (interim) and at the end of (post) chemotherapy. T2 weighted sequences and standard semi-dynamic

contrast-enhanced MRI was performed with a fat-suppressed T1 weighted spoiled gradient echo sequence, time 45–50 s per acquisition, repeated out to 8 min.

Final MRI response was assessed according to modified Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, and categorised as complete response (MRI CR), partial response (MRI PR), stable disease (MRI SD), or progressive disease (MRI PD) [24], based on the presence and size of enhancing masses and non-mass enhancement. No enhancement in the tumour bed or in a residual mass, or no enhancement above background parenchymal enhancement at any phase of contrast-enhanced imaging, were denoted MRI CR; an MRI PR occurred when a residual mass or area of non-mass enhancement had reduced by more than 30% in maximum diameter. MRI results were derived from the clinical report, with review of axillary findings on MRI re-reported by an experienced breast radiologist (SJV) blinded to the pathological outcome.

Axillary nodes were assessed on MRI as normal, abnormal or borderline on each of the three MRI scans according to nodal morphology and size on T2 weighted and contrast enhanced T1 weighted sequences. Normal lymph nodes were those with uniform cortical thicknesses no more than 2.5 mm. Borderline nodes were those with mild cortical thickening more than 2.5 mm, either uniform or eccentric, and abnormal nodes were those with clearly abnormal size and morphology. At ultrasound, cortical thickness more than 2.3 mm was described as abnormal. Where ultrasound nodal response had not been recorded, available images were reviewed and assessed retrospectively by a radiologist (NMG) blinded to the MRI response to treatment.

Pathological response in the primary breast tumour was classified as: [25]

1. Pathologic complete Response (pCR), no residual invasive disease present;
2. Near complete Response, the residual invasive disease has a percentage reduction in cellularity of $\geq 90\%$;
3. Partial Response, reduction in cellularity of $> 50\%$ and $< 90\%$;
4. Minimal Response, reduction in cellularity $1\text{--}50\%$;
5. No pathological response, 0% reduction in cellularity.

Axillary lymph nodes were considered negative on pathology if no macrometastasis (foci > 2.0 mm) was identified on standard haematoxylin and eosin staining. The presence of scarring, micrometastasis (Mic) (foci $0.2\text{--}2.0$ mm) or isolated tumour cells (ITC) (foci < 0.2 mm or < 200 cancer cells in one section) was recorded and analysed.

The response of the breast tumour on MRI, and of the axillary nodes on MRI and ultrasound, together with core biopsy tumour grade, tumour type and immunophenotype

were correlated with the final pathology response in the breast and the number of abnormal nodes in the nodal clearance specimens.

The data were plotted in contingency tables and the significance tests used were Chi squared, Fisher exact, and Pearson correlation using vassarstats.com. Sensitivity, specificity and univariate analysis was performed using SPSS v 22.0.

Results

Of 176 patients treated with NAC during the study period, 117 patients had core biopsy-confirmed axillary nodal metastasis prior to treatment. Eighty-seven patients had available MRI data for analysis from before, during and after NAC and thus formed the study cohort. This number included two patients who were planned to receive 4 cycles only of NAC, and had MRI before and after 4 cycles (called interim for analysis purposes), and 4 patients who received 6 cycles and had only pre-and post treatment MRI scans.

The median age was 50 years (range 24–79). Baseline characteristics are shown in Table 1. In eight patients, low-volume distant metastatic disease was identified after commencing NAC, which was continued and patients underwent surgery as planned. Sixty-eight patients (74.2%) received a combination of anthracycline-based chemotherapy (5-fluorouracil, epirubicin and cyclophosphamide) and

taxane, and 34 patients (39.1%) had trastuzumab in combination with chemotherapy (Table 1). Median time to surgery was 6 weeks (4–12 weeks) after the last cycle of chemotherapy. In one patient surgery was delayed for 12 weeks resulting from investigation of a suspicious liver lesion later confirmed as benign. Fifty-eight patients (66.7%) underwent mastectomy and 29 (33.3%) had breast conserving surgery. The median number of lymph nodes retrieved at axillary clearance was 18 (7–34). The baseline pathological features are detailed in Table 1.

Pathological assessment of breast tumour and axillary nodal response

In the breast, pCR was reported in 15 patients (17.2%), near CR in 21 patients (24.1%), PR in 41 patients (47.1%), minimal response in 2 patients (2.3%) and no response in 8 patients (9.2%) (Table 1).

Axillary node clearance pathological assessment revealed no residual lymph node macrometastasis in 33 patients (37.9%), including 10 patients with residual ITC or Mic identified. Twenty-eight patients (32.2%) had one or two lymph nodes with macrometastasis, whereas 26 patients (29.9%) had more than 2 lymph nodes with residual macrometastasis (Tables 1 & 2). Twenty-eight patients had ITC or Mic disease, of whom 10 had only ITC/Mic, 7 had also 1 or 2 nodes with macrometastasis, and 11 had more than 2 nodes with macrometastasis. In

Table 1 Baseline tumour pathology and treatment characteristics

	Total patients <i>n</i> = 87 <i>n</i> (%)				
cT stage	T1	T2	T3	T4	
	1 (1.1%)	53 (60.9%)	18 (20.7%)	15 (17.2%)	
cN stage	N1	N2	N3		
	76 (86%)	7 (9%)	4 (5%)		
Type of chemotherapy	Anthracycline only	Taxane only	Combination		
	14 (16.1%)	5 (5.7%)	68 (78.2%)		
Trastuzumab	Trastuzumab				
	34 (39.1%)				
Type of surgery	Breast conservation		Mastectomy		
	29 (33.3%)		58 (66.7%)		
Tumour grade	G1	G2	G3		
	1 (1.1%)	23 (26.4%)	63 (72.4%)		
Tumour type	Invasive ductal	Invasive lobular	Other		
	79 (90.8%)	4 (4.6%)	4 (4.6%)		
Immunophenotype	ER +/HER2 +	ER +/HER2	ER –/HER2	ER –/HER2 –	
	26 (29.9%)	30 (34.5%)	8 (9.2%)	23 (26.4%)	
Pathological response of tumour	Complete response	Near complete	Partial response	Minimal response	No response
	15 (17.2%)	21 (24.1%)	41 (47.1%)	2 (2.3%)	8 (9.2%)
Pathological assessment of nodes	No residual metastasis	ITC/ Mic only	1–2 nodes with macrometastasis	More than 2 nodes with metastasis	
	23 (26.4%)	10 (11.5%)	28 (32.3%)	26 (29.9%)	

Table 2 Patient and tumour factors and association with level of axillary nodal burden on pathology

	No residual macrometastatic nodes n (%)	1–2 residual metastatic nodes n (%)	More than 2 residual metastatic nodes n (%)	<i>p</i> -value
Total	33 (37.9%)	28 (32.2%)	26 (29.9%)	
Patient median age (years)	50.0	48.5	53.0	0.319
Trastuzumab given				
yes	18 (53%)	8 (23.5%)	8 (23.5%)	0.068
no	15 (28%)	20 (38%)	18 (34%)	
Type of chemo				
FEC	2 (14%)	7 (50%)	5 (36%)	0.325
Taxane	2 (40%)	2 (40%)	1 (20%)	
both	29 (43%)	19 (28%)	20 (29%)	
Tumour type				
Ductal	30 (38%)	27 (34%)	22 (28%)	0.015
Lobular	0 (0%)	0 (0%)	4 (100%)	
Other	3 (75%)	1 (25%)	0 (0%)	
Tumour grade				
1	0 (0%)	1 (100%)	0 (0%)	0.080
2	6 (26%)	12 (52%)	5 (22%)	
3	27 (43%)	15 (24%)	21 (33%)	
T staging				
T1	1 (100%)	0 (0%)	0 (0%)	0.188
T2	21 (40%)	21 (40%)	11 (20%)	
T3	7 (39%)	3 (17%)	8 (44%)	
T4	4 (27%)	4 (27%)	7 (46%)	
Immunophenotype				
ER + ve/HER2 + ve	13 (50%)	8 (31%)	5 (19%)	0.044
ER + ve/HER2 -ve	6 (20%)	15 (50%)	9 (30%)	
ER -ve/HER2 + ve	5 (63%)	0 (0%)	3 (37%)	
ER -ve/HER2 -ve	9 (39%)	5 (22%)	9 (39%)	

approximately half of the patients there was evidence of nodal scarring in response to treatment in one or more lymph nodes. Data were analysed including ITC and Mic disease as a separate group, with no statistical differences, and data shown in Table 2 include ITC and Mic disease categorised as no residual macrometastatic disease.

There was a statistically significant correlation between breast tumour and axillary response as assessed by pathology: 86.7% (13 of 15) of those with tumour pCR, and 52.4% (11 of 21) of those who achieved near complete response in the primary breast tumour had no residual axillary disease respectively. In comparison, only 19.5% (8 of 41) of those with partial response, and 10% (1 of 10) of those with no or minimal response in the breast tumour proved to have no residual axillary disease respectively ($r = 0.495$; $p < 0.00001$).

Core biopsy factors and MRI assessment of breast and axillary nodal response

Results of analysis of all treatment and tumour variables and association with nodal response to treatment are shown in Table 2. Patients with HER2 positive disease (including both oestrogen receptor (ER) positive and ER negative disease) had a significantly higher rate of nodal complete response ($p = 0.04$). Although only small numbers of patients with lobular tumours were included, all had high volume residual nodal disease (4 of 4 patients, $p = 0.015$) (Table 2).

MRI response in the breast correlated significantly with pathological response ($r = 0.690$; $p < 0.000001$).

Both interim and end-of-treatment MRI assessment of response in the breast correlated with nodal burden at ANC ($p < 0.0001$ for both) (Table 3) (Fig. 1). Only one of 10 patients (10%) with an MR CR at interim MRI had

Table 3 Presurgical imaging modalities and association with level of axillary nodal burden on pathology

	No residual macrometastatic nodes n (%)	1–2 residual metastatic nodes n (%)	More than 2 residual metastatic nodes n (%)	p-value
Total	33 (38%)	28 (32%)	26 (30%)	
MRI breast tumour phenotype:				
Mass	21 (41%)	20 (39%)	10 (20%)	0.091
Non-mass enhancement	4 (33%)	4 (33%)	4 (33%)	
Both	8 (33%)	4 (17%)	12 (50%)	
MRI breast interim chemo:				
Complete response	10 (90%)	0	1 (10%)	< 0.0001
Partial response	18 (40%)	18 (40%)	9 (20%)	
Stable disease	3 (11%)	9 (33%)	15 (56%)	
Progressive disease	0 (0%)	0 (0%)	0 (0%)	
MRI breast post chemo:				
Complete response	25 (64%)	9 (23%)	5 (13%)	< 0.0001
Partial response	6 (15%)	16 (40%)	18 (45%)	
Stable disease	2 (40%)	2 (40%)	1 (20%)	
Progressive disease	0 (0%)	1 (100%)	0 (0%)	
MRI axilla post chemo:				
Normal	21 (46%)	13 (28%)	12 (26%)	0.087
Borderline	7 (39%)	7 (39%)	4 (22%)	
Abnormal (partial response)	5 (31%)	3 (19%)	8 (50%)	
Abnormal	0 (0%)	5 (71%)	2 (29%)	




Fig. 1 Demonstrates the association of tumour response as predicted on interim-treatment breast MRI and the pathological findings in axillary nodes $r = 0.50$; $p < 0.0001$. There were no patients with tumours showing progressive disease at interim MRI. Key: No residual macrometastasis in axillary nodes = 0; residual macrometastasis in 1 or 2 nodes = 1–2; residual macrometastasis in more than 2 nodes = > 2

positive lymph nodes after treatment. In contrast, all those with stable disease on interim MRI had residual macroscopic nodal disease (no patients had progressive disease at interim MRI) (Table 3) (Fig. 1). The overall node-negative conversion rate was 40% for the MRI PR group, with a further 40% having 1–2 residual nodes, and 20% with more than 2 positive nodes (Fig. 1). Core biopsy tumour grade did not correlate with nodal response.

Axillary imaging to predict response in axillary nodes

The axilla was assessed on MRI in 87 patients, and on USS in only 48. There was no correlation with imaging assessment of the axilla at interim or end-of-treatment and nodal positivity rates, with high false-positive and false-negative rates for those with data available for axillary USS and for MRI (Table 3; Fig. 2). In the subgroup of patients with MRI-reported abnormal nodes prior to chemotherapy, and normal axillary MRI post-treatment ($n = 37$), there were no abnormal nodes on surgery in 18 patients (48.6%), 1–2 nodes in 9 (24.3%), and more than 2 residual positive nodes in 10 (27.0%). There was therefore a false-negative rate of MRI axillary assessment of 27% for those with higher nodal burden of residual disease. Of those with MRI reported abnormal axillary nodes after NAC, including nodes that remained abnormal but showed partial response to treatment, 5 of 23 (21.7%) had no residual axillary nodal disease at surgery,

while 8 (34.8%) had 1–2 nodes positive, and 10 (43.5%) had more than 2 positive nodes, thus a false-positive rate of 21.7%.

Discussion

We have shown in this series that 38% of patients will have no residual macrometastatic axillary disease after NAC, which is similar to that of NSABP B-18 and American College of Surgeons Oncology Group trial (ACOSOG Z1071) with 37 and 41% respectively [26], and as such these patients could be spared ANC, with consideration of axillary radiotherapy.

In the ACOSOG Z1071 trial the highest pCR rates in both the breast and axilla were seen in HER2 positive cancers at 45.4%, followed by triple negative cancers at 38.2%, whereas the pCR rate was only 11.4% in the hormone-receptor positive category [14]. The overall pCR rate of 17.2% in our study was in accordance with the expected rates taking in consideration that approximately two thirds of our study population were hormone-receptor positive [14]. Our data show a better response in nodal disease in HER2 positive tumours, with no response in axillary nodes in the small number of lobular cancers included.

The response in the breast at interim and end-of-treatment MRI was found to correlate well with the pathological response rates, as in previous studies [19–22].




Fig. 2 demonstrates the reported axillary response from MRI assessment post-treatment and the number of positive nodes from the axillary node clearance. There was no statistical correlation

This provides an opportunity to assess response in the breast and also, as shown in our data, to aid decision-making regarding axillary surgery. Amongst all breast imaging modalities, contrast-enhanced (DCE) MRI has the best accuracy and positive predictive value (PPV) for the presence of residual breast disease. Furthermore, it has the best NPV in predicting complete pathological response (pCR) [19].

Our study was retrospective, utilising diagnostic MRI images as performed in many breast centres, and as such the metric chosen for analysis is one that can be employed in any breast centre. We suggest that our results are more likely to be generalisable, since they are independent of the postprocessing platform utilised. Diffusion weighted imaging, although sensitive particularly in identification of pCR, has the issue of a current lack of standardisation across centres.

Both interim and end-of-treatment MRI were performed in our patient group. It is plausible patients whose tumours respond well at MRI after only 3–4 cycles are very likely to have good nodal response, but there was still a sizeable minority of patients with interim MRI PR who went on to have MRI CR on completion of NAC (around 30%). Our data therefore suggest that assessment of breast response on MRI should be performed towards the end of NAC with sufficient time to allow for surgical planning, but that a series of 3 MRIs during treatment may not be necessary.

Stratification of tumour response on breast MRI has been shown in our series to be indicative of axillary nodal response. In accordance with the results of a systematic review, we did not find that MRI assessment of the axillary nodes was helpful in this context, as there were high false-positive and false-negative rates [23]. This is despite the fact that the breast tumour response was evident at the time of reporting to the radiologist, and one might expect some bias towards favourable assessment of the axilla if breast tumour response is good, but our data do not support this. Thus use of MRI to assess the axilla does not aid decision making on axillary clearance in our series. Importantly, when the axilla normalised at MRI, over 54% of patients proved to have one or more residual macrometastases at ANC.

Axillary USS (AUS) was not performed after treatment in a number of patients in this series, as during the study period it did not influence the outcomes for the patient because of the local policy recommending ANC if nodal disease had been proven prior to NAC. For those in whom AUS results were available it did not appear to be useful in addition to breast MRI response. AUS has previously been shown to surpass other modalities in axillary lymph node assessment [19], although there has been a wide variability in the reported sensitivity (27–94%) and specificity (53–98%) [27, 28]. In order to

ascertain any additional benefit from AUS assessment of axillary nodes after ANC, we are now routinely performing this at the end of NAC.

This study has some limitations, with relatively small numbers of patients from a single institution. Nonetheless the results suggest that the findings are worthy of consideration in a larger cohort of patients, as the importance of breast MRI in prediction of axillary response after NAC has not been well studied thus far. Our data indicate that, taken together with tumour specific factors, breast MRI may be able to guide surgical decision making for the axilla in the increasing number of breast cancer patients treated with NAC.

Conclusions

Contrast-enhanced MRI assessed response in the primary breast tumour is very useful for predicting response in the axilla, but axillary node assessment of response by DCE-MRI is less accurate. An MRI complete response in the breast was the only imaging factor we found to predict for axillary response. If one considers that axillary radiotherapy or perhaps no further local treatment may be an acceptable alternative to ANC in patients with no macrometastatic axillary disease after NAC, then a third of patients in this series could have been spared ANC. From analysis of these data, our local policy has been changed to incorporate MRI breast response, immunophenotype tumour type including HER2 positive and non-lobular type tumours, and AUS where available to identify patients who now undergo SNB rather than ANC, and we are auditing this change of practice.

Abbreviations

ACOSOG: American College of Surgeons Oncology Group; ANC: Axillary node clearance; AUS: Axillary ultrasound scan; DCE MRI: Dynamic contrast enhanced magnetic resonance imaging; ER: Oestrogen receptor; FNR: False negative rate; HER2: Human epidermal growth factor receptor 2; ITC: Isolated tumour cells; Mic: Micrometastasis; MRI- CR: Magnetic resonance imaging complete response; MRI- PD: Magnetic resonance imaging progressive disease; MRI- PR: Magnetic resonance imaging partial response; MRI- SD: Magnetic resonance imaging stable disease; MRI: Magnetic resonance imaging; NAC: Neoadjuvant chemotherapy; NPV: Negative predictive value; NSABP: National Surgical Adjuvant Breast Project; pCR: Pathological complete response; PPV: Positive predictive value; RECIST: Response Evaluation Criteria in Solid Tumours; ROC: Receiver operating characteristic; SNB: Sentinel node biopsy

Acknowledgements

Not applicable.

Authors' contributions

SAH, SJV, NMG, AE, DJA, CAP, EJM contributed to study concepts and design. SAH, SJV, NMG, AE, EJM contributed data acquisition, including NMG and AE reviewing ultrasound images and SJV reviewing MRI imaging. SAH, SJV, NMG, AE contributed to quality control of data and algorithms. SAH, SJV, CAP, EJM, DJA, SA contributed to data analysis and interpretation. AE, EJM performed statistical analyses. All authors contributed to manuscript preparation, editing and review. All authors read and approved the final manuscript.

Funding

This study had no external funding source.

Availability of data and materials

The datasets generated during and/or analyses during the current study are not publicly available due to patient confidentiality but are available anonymised from the corresponding author on reasonable request.

Ethics approval and consent to participate

Local ethical approval from the Caldicott guardian was obtained for collection, analysis and presentation of data. This was a retrospective study and no consent to participate was required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Breast Surgery, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. ²Thirlestaine Breast Centre, Cheltenham, UK. ³Ninewells Hospital and Medical School, Dundee, UK. ⁴Department of Breast Radiology, Ninewells Hospital and Medical School, Dundee, UK. ⁵Department of Clinical Oncology, Ninewells Hospital and Medical School, Dundee, UK. ⁶Department of Breast Pathology, Ninewells Hospital and Medical School, Dundee, UK.

Received: 6 September 2019 Accepted: 12 December 2019

Published online: 26 December 2019

References

- Dixon JM. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer. *Breast Cancer Manag.* 2015;4:271–4. <https://doi.org/10.2217/bmt.15.25>.
- Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. *Ann Surg.* 1999;230:72–8.
- Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. *J Clin Oncol.* 1997;15:2483–93. <https://doi.org/10.1200/JCO.1997.15.7.2483>.
- Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. *Ann Surg Oncol.* 2012;19:3177–84. <https://doi.org/10.1245/s10434-012-2484-2>.
- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol.* 2005;23:3676–85. <https://doi.org/10.1200/JCO.2005.07.032>.
- Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. *J Clin Oncol.* 2005;23:2694–702. <https://doi.org/10.1200/JCO.2005.05.188>.
- Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta-analysis. *Acad Radiol.* 2009;16:551–63. <https://doi.org/10.1016/j.acra.2009.01.026>.
- Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. *Ann Surg.* 2009;250:558–66. <https://doi.org/10.1097/SLA.0b013e3181b8fd5e>.
- Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. *Lancet Oncol.* 2007;8:881–8. [https://doi.org/10.1016/S1470-2045\(07\)70278-4](https://doi.org/10.1016/S1470-2045(07)70278-4).
- Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. *Cancer.* 2000;89:2187–94. [https://doi.org/10.1002/1097-0142\(20001201\)89:11<2187::aid-cncr6>3.0.co;2-#](https://doi.org/10.1002/1097-0142(20001201)89:11<2187::aid-cncr6>3.0.co;2-#).
- Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. *J Clin Oncol.* 2000;18:3480–6. <https://doi.org/10.1200/JCO.2000.18.20.3480>.
- Classe J-M, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. *Breast Cancer Res Treat.* 2019;173:343–52. <https://doi.org/10.1007/s10549-018-5004-7>.
- Tee SR, Devane LA, Evoy D, Rothwell J, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. *Br J Surg.* 2018;105(12):1541–52. <https://doi.org/10.1002/bjs.10986>.
- Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. *Ann Surg.* 2014;260:608–14; discussion 614–6. <https://doi.org/10.1097/SLA.0000000000000924>.
- Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. *Lancet Oncol.* 2013;14:609–18. [https://doi.org/10.1016/S1470-2045\(13\)70166-9](https://doi.org/10.1016/S1470-2045(13)70166-9).
- Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. *J Clin Oncol.* 2015;33:258–64.
- Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). *Ann Surg.* 2016;263:802–7. <https://doi.org/10.1097/SLA.0000000000001375>.
- Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. *JAMA Surg.* 2017;152(7):665–70.
- Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, dynamic mammogram, ultrasound, and MRI in determining Postneoadjuvant pathologic tumor response in operable breast cancer patients. *Ann Surg Oncol.* 2011;18:3160–3. <https://doi.org/10.1245/s10434-011-1919-5>.
- Lobb MB, Prevost R, Smidt M, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. *Insights Imaging.* 2013;4:163–75.
- Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. *Radiology.* 2017;285:358–75.
- De Los SJ, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, et al. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. *Clin Breast Cancer.* 2011;11:312–9. <https://doi.org/10.1016/j.clbc.2011.06.007>.
- Schipper RJ, Moosdorff M, Beets-Tan RG, et al. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. *Eur J Radiol.* 2015;84:41–7.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45:228–47. <https://doi.org/10.1016/j.ejca.2008.10.026>.
- Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. *Arch Pathol.* 2009;133:633–42.
- Gangi A, Choi M, Giuliano AE. Management of the axilla after neoadjuvant therapy: current data and controversies. *Curr Breast Cancer Rep.* 2014;6:283–8. <https://doi.org/10.1007/s12609-014-0167-7>.
- Mobbs LM, Jannick EAS, Weaver DL, Harvey SC. The accuracy of Sonography in detecting abnormal axillary lymph nodes when breast

cancer is present. *J Diagnostic Med Sonogr.* 2005;21:297–303.

<https://doi.org/10.1177/8756479305278268>.

28. Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (Alliance). *J Clin Oncol.* 2015;33:3386–93. <https://doi.org/10.1200/JCO.2014.57.8401>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

